Alto Neuroscience (ANRO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ANRO Alto Neuroscience

Watchlist

13.620
+0.620+4.77%

Close Sep 13 16:00 ET

13.620
0.0000.00%

Post 20:01 ET

367.18MMarket Cap-7370P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Alto Neuroscience Insiders Placed Bullish Bets Worth US$638.5k
Yahoo FinanceSep 11 09:08 ET
Baird Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $32
Moomoo NewsSep 11 03:31 ET · Ratings
Buy Rating Affirmed for Alto Neuroscience, Inc. Amid Promising ALTO-100 Clinical Developments
TipRanksSep 11 02:35 ET · Ratings
Alto Neuroscience Analyst Ratings
BenzingaSep 10 08:50 ET · Ratings
Wedbush Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $29
Moomoo NewsSep 10 08:31 ET · Ratings
Analysts Are Bullish on These NA Stocks: Alto Neuroscience, Inc. (ANRO), Rubrik, Inc. Class A (RBRK)
TipRanksSep 10 07:20 ET · Ratings

Comments

Sherry922

Sep 9 09:28

Columns ANRO analysis

$Alto Neuroscience (ANRO.US)$ Alto Neuroscience, Inc. is a biotechnology company focused on developing personalized mental health treatments and is committed to improving the diagnosis and treatment of mental illness through precision medicine. The company mainly provides customized treatment plans for different individuals through the combination of neuroscience, artificial intelligence and data analysis.
Core business and technology:
Personalized Medication: Alto Neuroscience’s goa...

Jaguar8

Apr 23 07:36

$Alto Neuroscience (ANRO.US)$
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...

Moomoo AI

Feb 27 11:21

Investment firms see Alto Neuroscience's biomarker approach as a potential boost for clinical trials and patient outcomes. They predict a high stock risk/reward into 2H 2024/1H 2025 readouts, with a possible 100%-200% rise on positive data.